Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 19/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 8/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3216200 | 1.00 | P2RY12 (1.00) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL29409601 | 1.00 | P2RY12 (1.00) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4996029 | 0.97 | P2RY12 (0.94) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4876836 | 0.94 | P2RY12 (0.90) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4871252 | 0.94 | P2RY12 (0.89) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4877635 | 0.94 | P2RY12 (0.92) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4872315 | 0.94 | P2RY12 (0.91) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4871555 | 0.94 | P2RY12 (1.00) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4878733 | 0.94 | P2RY12 (0.88) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4880786 | 0.93 | P2RY12 (0.87) | P2RY12CYP2C9CYP3A4CHRM2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025229484-A1 | PURINERGIC P2 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF CONGENITAL SIDEROBLASTIC ANEMIAS | UNIVERSITÀ DEGLI STUDI DI BARI ALDO MORO (IT) | 2025-11-06 | — | — | WO | claimed |
| US-20260091147-A1 | METHOD FOR DETECTING INNATE IMMUNE ACTION IN VIVO USING GPR84-PET | THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIV (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4655302-A1 | TYRO3 SELECTIVE INHIBITORS AND USES THEREOF | The University of North Carolina at Chapel Hill (US) | 2025-12-03 | — | — | EP | disclosed |
| WO-2025229484-A1 | PURINERGIC P2 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF CONGENITAL SIDEROBLASTIC ANEMIAS | UNIVERSITÀ DEGLI STUDI DI BARI ALDO MORO (IT) | 2025-11-06 | — | — | WO | disclosed |
| WO-2024220480-A2 | METHOD FOR DETECTING INNATE IMMUNE ACTION IN VIVO USING GPR84-PET | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024159097-A1 | TYRO3 SELECTIVE INHIBITORS AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-08-02 | — | — | WO | disclosed |
| EP-4399282-A2 | COMPOSITIONS OF INDUCED PLURIPOTENT STEM CELL-DERIVED CELLS AND METHODS OF USE THEREOF | Fujifilm Cellular Dynamics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-118234849-A | Compositions for inducing pluripotent stem cell-derived cells and methods of use thereof | 富士胶片细胞动力公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20230183644-A1 | COMPOSITIONS OF INDUCED PLURIPOTENT STEM CELL-DERIVED CELLS AND METHODS OF USE THEREOF | FUJIFILM Cellular Dynamics, Inc. (US) | 2023-06-15 | — | — | US | disclosed |
| WO-2023039567-A2 | COMPOSITIONS OF INDUCED PLURIPOTENT STEM CELL-DERIVED CELLS AND METHODS OF USE THEREOF | FUJIFILM Cellular Dynamics, Inc. (US) | 2023-03-16 | — | — | WO | disclosed |
| US-20220251516-A1 | METHODS FOR THE PRODUCTION OF MULTIPLE LINEAGES FROM INDUCED PLURIPOTENT STEM CELLS USING CHARGED SURFACES | FUJIFILM Cellular Dynamics, Inc. (US) | 2022-08-11 | — | — | US | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| EP-3983528-A1 | METHODS FOR THE PRODUCTION OF MULTIPLE LINEAGES FROM INDUCED PLURIPOTENT STEM CELLS USING CHARGED SURFACES | FUJIFILM Cellular Dynamics, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-114174493-A | Methods for generating multiple lineages from induced pluripotent stem cells using charged surfaces | 富士胶片细胞动力公司 | 2022-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091147-A1 | METHOD FOR DETECTING INNATE IMMUNE ACTION IN VIVO USING GPR84-PET | GPR84, GPR65, GPR88 | P2RY12 155/4885CYP2C9 3594/4885CYP3A4 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.